Clin2
NCT07489209Possibly a fitRecruiting

Study of EDP167 for homozygous familial hypercholesterolemia

Homozygous Familial Hypercholesterolemia (HoFH)

Part of Genetic & congenital, Hormones & metabolism clinical trials.

This trial tests a new drug, EDP167, for people with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes very high cholesterol. The goal is to see if EDP167 can lower 'bad' cholesterol (LDL-C).

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older and weigh at least 40 kg.
  • You have a genetic or clinical diagnosis of HoFH.
  • Your fasting 'bad' cholesterol (LDL-C) is at least 2.6 mmol/L.
  • You are on a stable, low-fat diet and lipid-lowering medications.
  • You have not used certain investigational drugs or procedures (like apheresis) recently.
  • You agree to use contraception if applicable and are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07470723Recruiting
Familial Hypercholesterolemia in pregnancy and newborns study

This study looks at how familial hypercholesterolemia (a genetic condition that causes high cholesterol) affects mothers and their newborns. It aims to learn more about cholesterol levels during pregnancy and the baby's first week of life.

Madison, Wisconsin
NCT07491172Recruiting· Phase 1
Trial of CTX310 for stubborn high cholesterol and fats

This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.

Hialeah, Florida
NCT07465263Recruiting· Phase 3
Study of SYH2053 Injection for High Cholesterol in HeFH

This study tests a new injection called SYH2053 for people with HeFH, a genetic condition that causes very high cholesterol. It looks at whether the injection can safely lower LDL cholesterol when added to standard statin therapy.

Beijing, Beijing Municipality
NCT07591298Recruiting· Phase 2
SYH2070 injection for homozygous familial high cholesterol

This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.

Changsha, Hunan
NCT07450378Not yet recruiting· Phase 3
A new drug for high cholesterol from family genes

This trial tests an experimental medication called QLC7401 for people with a genetic condition that causes very high cholesterol. It aims to lower cholesterol levels safely and may be an option for those who need better control.

NCT07353398Not yet recruiting· Early Phase 1
Early study of ART002g1 for inherited high cholesterol

This trial tests a new injection called ART002g1 for people with a genetic condition that causes very high cholesterol. It aims to see if the drug is safe and can help lower cholesterol levels.

Shanghai

Hear when a new Homozygous Familial Hypercholesterolemia (HoFH) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.